Psoriasis

New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.

With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.

Arcutis has announced that the FDA has accepted the New Drug Application for roflumilast cream for adults and adolescent patients with plaque psoriasis.

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.

The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

In a video for Dermatology Times®, Mark Lebwohl, MD, details how to match patients with the right psoriasis treatment for their specific needs.

A phase 3 study evaluated apremilast as a treatment for patients with mild to moderate psoriasis.

In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.

In this episode, we dive into the background of the “The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas.” Adam Friedman, MD, and Misty Eleryan MD, MS, describe their process to creating this new dermatologic resource.

The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

The approval was supported by promising phase 3 data of the VOLTAIRE-X clinical trial.

A review of apremilast combination therapies was recently published in the Journal of Drugs in Dermatology, examining treatment efficacy and safety.

A recent study examines systemic and phototherapy treatment utilization and drug survival in pediatric patients with psoriasis.

Arcutis Biotherapeutics, Inc has released data from its DERMIS-1 and DERMIS-2 Phase 3 pivotal studies demonstrating that the topical significantly reduced the burden and severity of itch.

Two poster presentations at the EADV 30th annual conference showed the efficacy of roflumilast foam for nonsteroidal treatment of psoriasis or seborrheic dermatitis.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

The new data examines delivery system efficacy of either 1 secukinumab 300-mg dose in an autoinjector vs 2 doses of secukinumab 150-mg 1 mL pre-filled syringes.

This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.

Even with patient hesitancy, treating PPP with gentian violet and chemical peels could help patients avoid biologics.

The FDA has approved halobetasol propionate foam, 0.05% (Lexette; Mayne Pharma), a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.